Abstracts tagged "Adalimumab"

Abstract Number: 2504 • 2016 ACR/ARHP Annual Meeting
Impaired Vasodilator Function in Rheumatoid Arthritis Patients Who Flared Due to Stopping Adalimumab or Etanercept
Gerard A Rongen¹, Iris van Ingen² and Tim L Jansen^3,4, ¹Internal Medicine/Pharmacology and Toxicology, Radboud UMC, Nijmegen, Netherlands, ²Rheumatology, RadboudUMC, Nijmegen, Netherlands, ³Rheumatology, VieCuri Medical Centre, Venlo, Netherlands, ⁴Scientific IQ HealthCare, Radboud UMC, Nijmegen, Netherlands
Background/Purpose: Chronic inflammation in rheumatoid arthritis (RA) is associated with an increased cardiovascular risk, possibly due to disrupted vascular vasodilation. Within 12 weeks adalimumab and…
Abstract Number: 63 • 2016 ACR/ARHP Annual Meeting
Identification of Immune Gene Modules in Good Responders to Adalimumab in Rheumatoid Arthritis
James OIiver¹, Darren Plant², Gisela Orozco¹, Samantha Smith¹, Kimme L. Hyrich³, Ann Morgan⁴, John Isaacs⁵, Anthony G. Wilson⁶ and Anne Barton^1,2, ¹Arthritis Research UK, Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust, Manchester, United Kingdom, ³Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, Great Britain, ⁵Institute of Cellular Medicine, Newcastle University and National Institute for Health Research Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom, ⁶UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland
Background/Purpose: Despite the revolutionary impact of TNF inhibitor (TNFi) therapy in rheumatoid arthritis (RA), up to 40% of patients fail to respond adequately. Whilst non-responder…
Abstract Number: 698 • 2016 ACR/ARHP Annual Meeting
Performance of Modified Minimal Disease Activity (MDA) in Patients with Peripheral Spondyloarthritis
Laura C. Coates¹, Sonya Abraham², William Tillett³, Philip J Mease⁴, Sofia Ramiro⁵, Yinglin Xia⁶, Xin Wang⁷, Aileen L. Pangan⁷ and In-Ho Song⁷, ¹University of Leeds, Leeds, United Kingdom, ²NIHR/Wellcome CRF, Imperial College Healthcare NHS Trust, London, United Kingdom, ³Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶University of Illinois at Chicago, Chicago, IL, ⁷AbbVie Inc., North Chicago, IL
Background/Purpose: Due to lack of validated outcome measures in non-psoriatic peripheral spondyloarthritis (pSpA), recent studies in this patient (pt) population have used varying endpoints [1].…
Abstract Number: 2526 • 2016 ACR/ARHP Annual Meeting
TNF Blocker Concentrations or Detection of Antibodies Against Anti-TNF before a Tapering Process Are Not Predictive to Relapse
Hubert Marotte^1,2, Mélanie Rinaudo-Gaujous³, Stéphane Paul^3,4 and Bruno Fautrel⁵, ¹SAINBIOSE INSERM U1059 and Rheumatology department, University of Lyon and University Hospital of Saint Etienne, Saint Etienne, France, ²Rheumatology Department, University Hospital of Saint-Etienne, Saint-Etienne, France, ³Laboratory of Immunology and immunomonitoring, CIC CIE3 Inserm Vaccinology, GIMAP EA3064, Hôpital Nord, Saint-Etienne, France, ⁴Centre Hospitalier Universitaire de Saint-Étienne, Saint-Étienne, France, ⁵Rheumatology, Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: The goal of rheumatoid arthritis (RA) strategy is to reach remission or at least a low disease activity. When this goal is reached, no…
Abstract Number: 80 • 2016 ACR/ARHP Annual Meeting
Impact of a Patient Support Program on Abandonment of Adalimumab Treatment Initiation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis
Philip Mease¹, Manish Mittal², Martha Skup², Matthew Davis³, Arijit Ganguli², Scott Johnson³ and Michael Schiff⁴, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²AbbVie Inc., North Chicago, IL, ³Medicus Economics, LLC, Milton, MA, ⁴University of Colorado, Greenwood Village, CO
Background/Purpose: Treatment abandonment (failure to start therapy after prescription) is common among patients (pts) prescribed specialty pharmaceuticals. AbbVie offers a pt support program (PSP) for…
Abstract Number: 700 • 2016 ACR/ARHP Annual Meeting
Incidence of Inflammatory Bowel Disease Events in Adalimumab (HUMIRA) Clinical Trials Across Indications
Jeffrey R. Curtis¹, Dirk Elewaut², Su Chen³, Maja Hojnik⁴, Navit Naveh⁵ and Jaclyn K. Anderson³, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²VIB Inflammation Research Center, University of Ghent, Ghent, Belgium, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie, Ljubljana, Slovenia, ⁵AbbVie, Hod HaSharon, Israel
Background/Purpose: Adalimumab (ADA) is approved for treatment of Crohn’s disease (CD) and ulcerative colitis (UC); therefore, it is postulated that new onset or flare of…
Abstract Number: 2531 • 2016 ACR/ARHP Annual Meeting
Impact of Participation in the Adalimumab (Humira) Patient Support Program on Functional and Clinical Outcomes Among Patients with Rheumatoid Arthritis: Passion Study
Filip van Den Bosch¹, Andrew Östör², Siegfried Wassenberg³, Jaclyn K. Anderson⁴, Naijun Chen⁵, Chen Wang⁴, Vishvas Garg⁵ and Jasmina Kalabic⁶, ¹Rheumatology, Ghent University Hospital, Gent, Belgium, ²Addenbrooke's Hospital, Cambridge, United Kingdom, ³Rheumazentrum, Ratingen, Germany, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Inc, North Chicago, IL, ⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Patients (pt) with Rheumatoid arthritis (RA) who are treated with adalimumab (ADA) are offered a Patient Support Program (PSP) with variety of services. To…
Abstract Number: 84 • 2016 ACR/ARHP Annual Meeting
Treatment Outcomes and Predictors of Patient Support Program Use Among Patients with Rheumatoid Arthritis: Results from a Post-Marketing Observational Study (PMOS)
Filip van Den Bosch¹, Siegfried Wassenberg², Andrew Östör³, Chen Wang⁴, Jasmina Kalabic⁵ and Vishvas Garg⁴, ¹Rheumatology, Ghent University Hospital, Gent, Belgium, ²Rheumazentrum, Ratingen, Germany, ³Addenbrooke's Hospital, Cambridge, United Kingdom, ⁴AbbVie Inc, North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Patient (pt) support programs (PSPs) are offered to Rheumatoid arthritis (RA) pts to help manage treatment of this chronic disease. Little information is available…
Abstract Number: 701 • 2016 ACR/ARHP Annual Meeting
In Patients with Ankylosing Spondylitis Treated with Adalimumab, Combination Therapy with DMARD, Increase the Serum Level of Adalimumab and Decrease Immunogenicity
José Rosas¹, Francisca Llinares-Tello², José Miguel Senabre-Gallego¹, Mariana Marco-Mingot³, Ana Pons¹, Xavier Barber⁴, Gregorio Santos-Soler¹, Esteban Salas-Heredia¹, Catalina Cano¹, Juan Molina³, Marina Sanchís⁴, Mario García-Carrasco⁵ and AIRE-MB Group, ¹Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ²Laboratory, Hospital Marina Baixa, Villajoyosa, Spain, ³Laboratory, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ⁴CIO, Universidad Miguel Hernández, Elche, Spain, ⁵Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: In patients with rheumatoid arthritis, methotrexate (MTX), improves the clinical efficacy of anti-TNF (TNFi), among other reasons, for reducing the immunogenicity. However, there are…
Abstract Number: 2601 • 2016 ACR/ARHP Annual Meeting
A Cytometric Assay for Monitoring Adalimumab Immunogenicity and Drug Concentrations Can Distinguish Anti-Adalimumab Antibodies from Interference
Morgan Casal¹, Manda Ramsey¹, Larry W. Moreland² and Christian Fernandez¹, ¹Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, ²Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Tumor necrosis factor inhibitor (TNFi) biologics are a mainstay of therapy for rheumatoid arthritis (RA) patients with disease-modifying antirheumatic drug failure. However, RA patients…
Abstract Number: 92 • 2016 ACR/ARHP Annual Meeting
Is Patient Support Program (PSP) Participation Associated with Longer Persistence and Greater Adherence Among New Users of Adalimumab?
Einav Srulovici^1,2, Vishvas Garg³, Adi Ghilai², Becca Feldman², Moshe Hoshen², Ran Balicer², Martha Skup⁴ and Maya Leventer-Roberts², ¹School of Nursing, University of Haifa, Haifa, Israel, ²Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel, ³AbbVie Inc, North Chicago, IL, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: In Israel, patients treated with adalimumab (ADA) can enroll in a patient support program (PSP) provided by AbbVie, which includes a home visit by…
Abstract Number: 735 • 2016 ACR/ARHP Annual Meeting
Impact of Time Since Diagnosis, Age, and Number of Prior Non-Steroidal Anti-Inflammatory Drugs on Response to Adalimumab (HUMIRA) in Patients with Ankylosing Spondylitis
Joachim Sieper¹, Atul A. Deodhar², Maja Hojnik³, Ying Zhang⁴ and Maxime Dougados⁵, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Oregon Health and Science University, Portland, OR, ³AbbVie, Ljubljana, Slovenia, ⁴AbbVie, North Chicago, IL, ⁵René Descartes University and Hôpital Cochin, Paris, France
Background/Purpose: Ankylosing spondylitis (AS) patients (pts) were found to respond better to TNF inhibitors (TNFi) if treated early in the disease course. The objective of…
Abstract Number: 2638 • 2016 ACR/ARHP Annual Meeting
In Vitro Expansion of Treg By Adaimumab Predicts Clinical Response to Therapy in Patients with Rheumatoid Arthritis
Dao Xuan Nguyen, Centre of Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Regulatory T cells (Treg) are potent suppressors of immune responses and are considered a pivotal element in resolving inflammation and autoimmunity. We have previously…
Abstract Number: 100 • 2016 ACR/ARHP Annual Meeting
Patient Support Program for Adalimumab-Treated Patients in Brazil: Impact on Patients’ Adherence and Persistence
Roger A. Levy¹, Vanessa Teich², Roberta Fernandes², Anna Gulart², Leonardo Chaves³, Vishvas Garg⁴ and Martha Skup⁵, ¹Rheumatology, Department of Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Sense Company, São Paulo, Brazil, ³AbbVie Inc., Chicago, IL, ⁴AbbVie Inc, North Chicago, IL, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: The Brazilian public healthcare system covers treatment with adalimumab for rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriatic arthritis, in line with local guidelines.…
Abstract Number: 1101 • 2016 ACR/ARHP Annual Meeting
Adalimumab:TNF Complexes Induce a Divergent Proteomic Profile in Human Osteoclast Precursors to That Resembling a Monocytic Cell
Bohdan P. Harvey¹, Chenqi Hu², Dongdong Wang², Yu Tian² and Zehra Kaymakcalan¹, ¹Global Biologics, AbbVie Bioresearch Center, Worcester, MA, ²DMPK-BA, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: TNF has been shown to contribute to osteoclastogenesis independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast (OC) development.…

« Previous Page
1
…
5
6
7
8
9
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].